Alliance for Natural Health
July 10, 2019

…that will cost $2.1 million.
The Food and Drug Administration (FDA) recently approved a gene therapy drug for a form of spinal muscular atrophy (SMA). Novartis is pricing the drug, Zolgensma, at $2.125 million, or $425,000 per year for five years.
The drug is meant to treat children under 2 years of age with SMA, an inherited disease that, in its most severe form, can cause infants to die or require permanent breathing support.
Novartis faces competition from Biogen for an SMA gene therapy drug. Biogen’s product, Spinraza, was approved in 2016 and also comes with an eye-catching price tag. Spinraza requires regular spinal infusions that cost $750,000 in the first year, then $375,000 per year thereafter.
Novartis noted that it is working with insurers to implement pay-over-time and other schemes to help patients get the drug.

Read more: